BrightPath Biotherapeutics Co., Ltd.
Developing novel cancer immunotherapies, including peptide vaccines and iPS-NKT cell therapies.
4594 | T
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- Japan
- Address:
- 川崎市川崎区殿町三丁目２５番２２号
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel cancer immunotherapies. The company's pipeline encompasses multiple platforms, including cancer peptide vaccines, immuno-modulators, and advanced cell therapies. A primary focus is its proprietary iPS-NKT platform, a novel allogeneic cell therapy that uses natural killer T-cells (NKT cells) derived from induced pluripotent stem cells (iPSCs) for cancer treatment. This technology enables the large-scale, homogeneous production of NKT cells, which are naturally rare. The company, formerly known as GreenPeptide, also develops peptide vaccines like GRN-1201, which has progressed to clinical trials. Its business model covers drug discovery, research, and early-phase clinical development.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for BrightPath Biotherapeutics Co., Ltd. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-20 09:01 |
Regulatory News Service
臨時報告書
|
Japanese | 22.8 KB | |
| 2025-06-19 08:36 |
Regulatory News Service
確認書
|
Japanese | 8.9 KB | |
| 2025-06-19 08:32 |
Regulatory News Service
内部統制報告書－第22期(2024/04/01－2025/03/31)
|
Japanese | 23.4 KB | |
| 2025-06-19 08:25 |
Annual Report
有価証券報告書－第22期(2024/04/01－2025/03/31)
|
Japanese | 933.5 KB | |
| 2024-11-08 07:35 |
Regulatory News Service
確認書
|
Japanese | 9.0 KB | |
| 2024-11-08 07:34 |
Interim Report
半期報告書－第22期(2024/04/01－2025/03/31)
|
Japanese | 224.9 KB | |
| 2024-06-21 09:07 |
Regulatory News Service
訂正有価証券届出書（組込方式）
|
Japanese | 254.0 KB | |
| 2024-06-21 08:34 |
Regulatory News Service
内部統制報告書－第21期(2023/04/01－2024/03/31)
|
Japanese | 23.2 KB | |
| 2024-06-21 08:33 |
Regulatory News Service
確認書
|
Japanese | 9.0 KB | |
| 2024-06-21 08:32 |
Annual Report
有価証券報告書－第21期(2023/04/01－2024/03/31)
|
Japanese | 990.5 KB | |
| 2024-06-19 08:00 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 513.9 KB | |
| 2024-02-09 07:12 |
Regulatory News Service
確認書
|
Japanese | 9.1 KB | |
| 2024-02-09 07:11 |
Quarterly Report
四半期報告書－第21期第3四半期(2023/10/01－2023/12/31)
|
Japanese | 195.3 KB | |
| 2023-11-15 07:27 |
Regulatory News Service
訂正有価証券届出書（組込方式）
|
Japanese | 183.0 KB | |
| 2023-11-14 07:56 |
Prospectus
有価証券届出書（組込方式）
|
Japanese | 332.0 KB |
Automate Your Workflow. Get a real-time feed of all BrightPath Biotherapeutics Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for BrightPath Biotherapeutics Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
